We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GM:NYSEGeneral Motors Company Analysis

Data as of 2026-08-23 - not real-time

$87.93

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

At $87.93, General Motors Company shows a bullish moving-average alignment, with shorter averages sitting above longer ones. The last 30 days have gained 12.9%. RSI sits at 58.4, which reads as neutral, and MACD momentum is bearish. Price has been bracketed by support at $83.59 and resistance at $91.85.
The shares look fair at 39.3 times earnings, though no sector average was available for comparison. The average analyst target implies 15.1% above today's level. The 0.82% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 33.2%, a beta of 1.07 and a maximum drawdown of 16.2%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.

Top Market Events

Automotive manufacturer General Motors NYSE:GM reported Q2 CY2026 results , with sales up 1.General Motors NYSE:GM and SAIC Motor agreed to extend their joint venture for another 20 years to deepen cooperation...Earnings results often indicate what direction a company will take in the months ahead.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 79.05
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 79.05
  • Analyst targets imply +15.1% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Analyst targets imply +15.1% versus the current price
  • P/E ratio of 39.3
  • Elevated debt-to-equity of 202

Key Metrics & Analysis

Financial Health

Revenue Growth1.90%
Profit Margin1.05%
P/E Ratio39.3
ROE3.16%
ROA2.25%
Debt/Equity202.34
P/B Ratio1.2
Op. Cash Flow$23.2B
Free Cash Flow$21.9B

Technical Analysis

TrendBullish
RSI58.4
Support$83.59
Resistance$91.85
MA 20$87.40
MA 50$82.14
MA 200$79.05
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair Value$221.89
Target Price$101.19
Upside/Downside15.08%
GradeFair
TypeBlend
Dividend Yield0.82%

Risk Assessment

Beta1.07
Volatility33.21%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.